Zydus, along with its subsidiaries and affiliates, has been granted the final approval by the USFDA for its Lenalidomide Capsules in two different strengths, 2.5mg and 20mg, which is also known as Revlimid® Capsules in the United States. This is a significant milestone for Zydus Lifesciences Limited in the pharmaceutical industry.
Zydus Lenalidomide Capsules: A Breakthrough Treatment for Cancer & Anemia, Set to Launch in the US Market, Manufactured in Ahmedabad
Zydus has developed Lenalidomide Capsules, an innovative medication used to treat various types of cancers by impeding cancer cells’ growth. The drug is also effective in treating anemia in patients with myelodysplastic syndromes (MDS), potentially reducing the need for blood transfusions. The drug will be launched soon in the US market and manufactured at the group’s state-of-the-art formulation manufacturing facility located in SEZ, Ahmedabad (India).
Zydus Lenalidomide Capsules: A Potential Blockbuster Drug with Annual Sales of USD 183 mn in the US (IQVIA MAT Dec. 2022)
Zydus’ Lenalidomide Capsules have the potential to become a blockbuster drug in the United States pharmaceutical market with annual sales of USD 183 mn, according to IQVIA MAT Dec. 2022 data. This impressive figure solidifies Lenalidomide’s position as a significant contributor to the pharmaceutical industry and highlights the growing demand for this innovative drug.
Zydus Continues to Expand Portfolio with 349 Approvals and Over 440* ANDA Filings Since FY 2003-04
Zydus has been steadily expanding its pharmaceutical portfolio and now boasts 349 approvals, having filed over 440* Abbreviated New Drug Applications (ANDAs) since the beginning of the filing process in FY 2003-04. This remarkable accomplishment reflects Zydus’ commitment to providing high-quality, affordable medications to patients worldwide.
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
For More Latest News Click Here